Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Empagliflozin

Drug and asset intelligence for Empagliflozin with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 3
Stage: Development stage unavailable

Sponsor company

Aurobindo Pharma →

Mechanism of action

SGLT2 Inhibitor

Recent signals(3)

CompetitiveJuly 20, 2026

Aurobindo Pharma submits ANDA for Empagliflozin

Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for Empagliflozin.

ClinicalJune 25, 2026

Boehringer Ingelheim Tests Vicadrostat with Empagliflozin in CKD Patients

A clinical trial is underway to evaluate the efficacy of vicadrostat combined with empagliflozin in adults with chronic kidney disease.

June 19, 2026

Aurobindo Pharma submits ANDA for Empagliflozin and Metformin Hydrochloride

Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for Empagliflozin and Metformin Hydrochloride.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(3)

Topline Data

Aurobindo Pharma — Empagliflozin

July 20, 2026 · N/A

Topline Data

Boehringer Ingelheim — empagliflozin

June 25, 2026 · N/A

Topline Data

Aurobindo Pharma — Empagliflozin

June 19, 2026 · N/A

Indications

Therapeutic areas

Diabetes · SGLT2 Inhibitor →

Diabetes · SGLT2 Inhibitor and Biguanide →

SGLT2 Inhibitor →

SGLT2 Inhibitor and Biguanide →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.